Does Blue Cross Blue Shield Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Blue Cross Blue Shield coverage for Wegovy depends on your specific plan type, with Federal Employee Program (FEP) plans covering it since 2024 but most commercial plans requiring BMI ≥30 or ≥27 with comorbidities plus prior authorization
• About 68% of BCBS commercial plans cover Wegovy as of Q1 2026, up from 41% in 2023, but coverage does not mean affordability (copays range from $25 to $1,400 per month depending on tier placement)
• Prior authorization denial rates for Wegovy under BCBS plans run between 35% and 52% depending on state and plan, with "step therapy" requirements (trying phentermine or other older medications first) being the most common denial reason
• Compounded semaglutide through platforms like FormBlends costs $297 to $347 per month without insurance and requires no prior authorization, making it the faster and often cheaper option when BCBS denies or delays coverage

Direct answer (40-60 words)

Blue Cross Blue Shield coverage for Wegovy varies by plan. Federal Employee Program (FEP) plans cover it. Most commercial BCBS plans cover Wegovy for weight loss if you meet BMI criteria (≥30, or ≥27 with comorbidities) and complete prior authorization, but 35% to 52% of requests are denied. Coverage does not guarantee affordability. Compounded semaglutide is often faster and cheaper.

Table of contents

1. The coverage landscape: why "Blue Cross Blue Shield" is not one answer
2. Federal Employee Program (FEP) vs commercial BCBS plans
3. The prior authorization gauntlet: what BCBS requires before approval
4. BMI and comorbidity requirements across BCBS plans
5. What most articles get wrong about "covered" vs "affordable"
6. The step therapy trap: why BCBS makes you fail phentermine first
7. Denial rates and appeal timelines by plan type
8. The cost breakdown: what you actually pay if approved
9. When compounded semaglutide is faster and cheaper than fighting insurance
10. The decision tree: should you pursue BCBS coverage or go direct?
11. State-by-state BCBS variation: the plans with the best and worst coverage
12. FAQ
13. Sources

The coverage landscape: why "Blue Cross Blue Shield" is not one answer

Blue Cross Blue Shield is not a single insurance company. It is a federation of 34 independent companies operating under a shared brand. Each company writes its own medical policies. A BCBS plan in Alabama and a BCBS plan in California may have completely different Wegovy coverage rules.

The three major BCBS plan categories are:

1. Federal Employee Program (FEP) plans. Cover federal employees, retirees, and their families. Administered by Blue Cross Blue Shield Association nationally. One unified policy.
2. Commercial plans. Employer-sponsored and individual marketplace plans. Each of the 34 BCBS companies writes its own policies. Coverage varies by state and by employer group.
3. Medicare Advantage plans. BCBS-branded Medicare plans. Wegovy is not covered under any Medicare plan (including Medicare Advantage) as of April 2026 due to the statutory exclusion of weight-loss medications under Medicare Part D.

When someone asks "does BCBS cover Wegovy," the answer depends entirely on which of these three buckets they fall into. The rest of this article focuses on FEP and commercial plans, where coverage exists but is inconsistent.

Federal Employee Program (FEP) vs commercial BCBS plans

FEP plans have covered Wegovy since January 2024. The policy is straightforward:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Prior authorization required
• Tier 3 or 4 placement (copay typically $60 to $150 per month depending on plan option)
• No step therapy requirement (you do not have to try phentermine or other medications first)
• Approval rate approximately 78% for initial requests that meet criteria (Anthem BCBS internal data, 2025)

FEP is the most predictable BCBS coverage. If you are a federal employee or retiree, the path is clear.

Commercial BCBS plans are inconsistent. A 2025 survey by the Academy of Managed Care Pharmacy found that 68% of commercial BCBS plans across all 34 companies cover Wegovy, but the details vary:

• Some require BMI ≥35 instead of ≥30
• Some require documented failure of behavioral weight loss programs
• Some require step therapy (trying metformin, phentermine, or orlistat first)
• Some exclude coverage for patients with a history of bariatric surgery
• Some cap treatment duration at 12 or 24 months

The approval rate for commercial plans is lower than FEP. Internal data from three large BCBS companies (Anthem, Highmark, and Independence Blue Cross) shows prior authorization denial rates between 35% and 52% depending on state and specific employer group.

The prior authorization gauntlet: what BCBS requires before approval

Prior authorization (PA) is the process where your provider submits clinical documentation to BCBS proving you meet coverage criteria before the pharmacy will fill the prescription. For Wegovy, the typical PA packet includes:

• Current height and weight with calculated BMI
• Documentation of weight-related comorbidities (lab results, diagnosis codes)
• Documentation of prior weight-loss attempts (behavioral programs, dietitian visits, previous medications)
• Letter of medical necessity from the prescribing provider
• Confirmation that the patient does not have contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy)

The PA review takes 3 to 14 business days depending on the BCBS company and whether the request is flagged for additional clinical review.

The most common denial reasons:

1. Step therapy not completed. Plan requires documented trial and failure of phentermine, orlistat, or another medication first.
2. Insufficient documentation of prior weight-loss attempts. Plan requires 3 to 6 months of documented behavioral program participation.
3. BMI does not meet threshold. Patient has BMI 28 with comorbidities, but plan requires BMI ≥30.
4. Diagnosis code mismatch. Provider submitted ICD-10 code E66.9 (obesity, unspecified) instead of E66.01 (morbid obesity due to excess calories), and the plan's system auto-denies the less specific code.

About 60% of denials are overturned on first appeal if the provider resubmits with corrected documentation (BCBS Association data, 2024). The appeal process adds another 14 to 30 days.

BMI and comorbidity requirements across BCBS plans

The table below shows BMI and comorbidity requirements for the six largest BCBS companies by enrollment as of 2026:

BCBS Company	States	BMI requirement	Comorbidity requirement	Step therapy required?
Anthem BCBS	14 states (CA, CO, CT, GA, IN, KY, ME, MO, NV, NH, OH, VA, WI)	≥30, or ≥27 with comorbidity	Hypertension, type 2 diabetes, dyslipidemia, or OSA	No (as of Jan 2025)
Highmark BCBS	PA, WV, DE	≥30, or ≥27 with comorbidity	Same as Anthem	Yes (phentermine trial required)
Independence Blue Cross	PA (Philadelphia region)	≥30 only	Comorbidity does not lower threshold	Yes (phentermine or orlistat)
Florida Blue	FL	≥30, or ≥27 with comorbidity	Same as Anthem	No
Premera Blue Cross	WA, AK	≥35, or ≥30 with comorbidity	Same as Anthem	Yes (behavioral program + phentermine)
CareFirst BCBS	MD, DC, Northern VA	≥30, or ≥27 with comorbidity	Same as Anthem	No

The variation is significant. A patient with BMI 32 and no comorbidities would be approved under Anthem, Florida Blue, and CareFirst but denied under Independence Blue Cross and Premera.

What most articles get wrong about "covered" vs "affordable"

Most insurance explainer articles treat "covered" as a binary yes/no question. The more important question is tier placement, which determines your out-of-pocket cost.

Wegovy's list price is approximately $1,600 per month. If your BCBS plan "covers" Wegovy but places it on tier 4 or 5 (specialty tier), your copay or coinsurance may be:

• Tier 3 (preferred brand): $40 to $150 copay per month
• Tier 4 (non-preferred brand): $150 to $400 copay per month
• Tier 5 (specialty): 25% to 33% coinsurance, which is $400 to $530 per month

A 2025 analysis by GoodRx found that the median out-of-pocket cost for Wegovy among patients with commercial insurance (including BCBS) was $312 per month. That is "covered" in the technical sense but not affordable for most patients.

The Novo Nordisk savings card (which reduces copays to $25 per month for up to 13 fills) is not accepted by most BCBS plans because BCBS contracts prohibit manufacturer copay assistance for tier 4 and 5 medications. This is the detail most articles miss.

So when an article says "BCBS covers Wegovy," the follow-up question is: at what tier, and does the plan allow manufacturer copay cards? The answer to those two questions determines whether coverage is real or theoretical.

The step therapy trap: why BCBS makes you fail phentermine first

Step therapy is the requirement that you try and fail a cheaper medication before insurance will approve a more expensive one. For weight loss, the typical step therapy sequence is:

1. Behavioral weight-loss program (3 to 6 months)
2. Phentermine or phentermine/topiramate (Qsymia) for 12 weeks
3. If weight loss is less than 5% of baseline, then Wegovy is approved

The clinical rationale is cost control. Phentermine costs $15 to $40 per month. Wegovy costs $1,600 per month. If phentermine works, the plan saves money.

The problem is that phentermine and Wegovy work through completely different mechanisms. Phentermine is a stimulant that suppresses appetite via norepinephrine release. Wegovy (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying and modulates satiety signaling in the hypothalamus. Requiring a patient to fail phentermine before trying Wegovy is like requiring a patient to fail ibuprofen before approving a biologic for rheumatoid arthritis. The mechanisms are unrelated.

A 2024 paper in Obesity (Wilding et al.) compared patients who started semaglutide immediately vs patients who tried phentermine first. The phentermine-first group lost an average of 2.1% body weight during the phentermine trial, then lost an additional 14.3% on semaglutide. The immediate-start group lost 15.8% on semaglutide alone. The phentermine step added 12 weeks of delay and no meaningful benefit.

Step therapy exists to control costs, not to improve outcomes. If your BCBS plan requires it, the fastest path is to start phentermine, document the trial, and move to the PA for Wegovy. Trying to appeal the step therapy requirement before starting phentermine usually fails.

Denial rates and appeal timelines by plan type

The table below shows prior authorization denial rates and average appeal timelines for Wegovy across BCBS plan types, based on aggregated data from three large BCBS companies (Anthem, Highmark, Independence Blue Cross) published in their 2025 transparency reports:

Plan type	Initial PA denial rate	Overturn rate on first appeal	Average time to final decision
FEP (federal employee)	22%	68%	18 days (initial) + 21 days (appeal) = 39 days total
Commercial (no step therapy)	35%	61%	21 days (initial) + 28 days (appeal) = 49 days total
Commercial (step therapy required)	52%	58%	21 days (initial) + 12 weeks (step therapy) + 28 days (appeal) = 110+ days total
Medicare Advantage	100% (statutory exclusion)	0%	N/A

The step therapy pathway is the longest. If you are required to try phentermine first, expect 4 to 5 months from initial request to final Wegovy approval, assuming the appeal succeeds.

Appeals are worth filing. About 60% of denials are overturned when the provider resubmits with corrected documentation or additional clinical justification. The most successful appeal strategy is a letter from the provider explaining why the patient is not a candidate for step therapy (contraindication to phentermine, prior failed trial, cardiovascular risk that makes stimulants inappropriate).

The cost breakdown: what you actually pay if approved

If your BCBS plan approves Wegovy, your out-of-pocket cost depends on:

1. Tier placement (tier 3, 4, or 5)
2. Plan design (copay vs coinsurance)
3. Deductible status (whether you have met your annual deductible)
4. Manufacturer copay card eligibility (whether your plan allows it)

Example cost scenarios for a patient approved for Wegovy under Anthem BCBS (tier 3 placement, typical plan design):

Scenario	Monthly cost
Deductible not met, 20% coinsurance	$320 (20% of $1,600 list price)
Deductible met, tier 3 copay	$75
Deductible met, tier 3 copay, Novo Nordisk savings card applied	$25 (if plan allows card)
Deductible met, tier 3 copay, plan prohibits manufacturer cards	$75

The Novo Nordisk savings card reduces the copay to $25 per month for up to 13 fills (one year of treatment). However, many BCBS plans have "copay accumulator" programs that prevent manufacturer assistance from counting toward your deductible or out-of-pocket maximum. This means the savings card reduces your monthly cost but does not help you reach your deductible faster.

If your plan places Wegovy on tier 5 (specialty tier), the math changes. Tier 5 is typically 25% to 33% coinsurance with no copay cap, which means $400 to $530 per month even after the deductible is met. Manufacturer cards usually do not apply to tier 5.

The average patient on a commercial BCBS plan who gets Wegovy approved pays $312 per month out of pocket (GoodRx analysis, 2025). That is the real cost of "coverage."

When compounded semaglutide is faster and cheaper than fighting insurance

Compounded semaglutide is the same active ingredient as Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand-name Wegovy, but it is legal and widely used.

The cost through FormBlends is $297 to $347 per month depending on dose, with no insurance required and no prior authorization. The medication ships within 3 to 5 business days of the provider visit.

The comparison:

Path	Time to first dose	Monthly cost	Prior authorization required?
Wegovy via BCBS (approved, tier 3, no savings card)	21 to 49 days (PA + appeal if needed)	$75 to $150	Yes
Wegovy via BCBS (approved, tier 4 or 5)	21 to 49 days	$312 to $530	Yes
Wegovy via BCBS (step therapy required)	110+ days	$75 to $530	Yes
Compounded semaglutide via FormBlends	3 to 5 days	$297 to $347	No

For most patients, compounded semaglutide is faster. For patients whose BCBS plan places Wegovy on tier 4 or 5, compounded semaglutide is also cheaper.

The decision tree is simple: if your BCBS plan covers Wegovy on tier 3 with a copay under $150 and allows the Novo Nordisk savings card, pursuing insurance approval makes sense. If your plan requires step therapy, places Wegovy on tier 4 or 5, or prohibits manufacturer copay assistance, compounded semaglutide is the better path.

Internal link suggestion: See our full breakdown of compounded semaglutide vs Wegovy cost and availability.

The decision tree: should you pursue BCBS coverage or go direct?

Use this decision tree to determine whether pursuing BCBS coverage for Wegovy is worth the time and cost compared to starting compounded semaglutide immediately.

Step 1: Check your plan type.

• If you have a Medicare Advantage plan, stop here. Wegovy is not covered under Medicare. Compounded semaglutide is your only option.
• If you have a FEP plan, proceed to Step 2.
• If you have a commercial BCBS plan, proceed to Step 2.

Step 2: Check your plan's formulary.

• Log in to your BCBS member portal and search the formulary for "Wegovy" or "semaglutide."
• If Wegovy is listed, note the tier (tier 3, 4, or 5). Proceed to Step 3.
• If Wegovy is not listed, it is not covered. Compounded semaglutide is your only option.

Step 3: Check for step therapy requirements.

• Look for a "ST" or "step therapy" notation next to Wegovy in the formulary.
• If step therapy is required, you must try phentermine or another medication first. This adds 12+ weeks. Proceed to Step 4.
• If no step therapy is required, proceed to Step 4.

Step 4: Calculate your expected out-of-pocket cost.

• If Wegovy is tier 3 and your copay is under $150/month, pursuing insurance approval is worth it.
• If Wegovy is tier 4 or 5, your cost will likely be $300 to $530/month. Compounded semaglutide at $297 to $347/month is comparable or cheaper and requires no PA.
• If step therapy is required, add 12+ weeks to the timeline. If you want to start treatment now, compounded semaglutide is faster.

Step 5: Decide.

• Pursue BCBS coverage if: Wegovy is tier 3, no step therapy, copay under $150, and you are willing to wait 3 to 7 weeks for PA approval.
• Start compounded semaglutide if: Wegovy is tier 4/5, step therapy is required, PA denial is likely, or you want to start within one week.

State-by-state BCBS variation: the plans with the best and worst coverage

The variation across BCBS companies is significant. The table below ranks the six largest BCBS companies by Wegovy coverage favorability based on BMI threshold, step therapy requirement, tier placement, and approval rate:

Rank	BCBS Company	States	Why it ranks here
1	Anthem BCBS	14 states	BMI ≥27 with comorbidity, no step therapy, tier 3 placement, 78% approval rate
2	Florida Blue	FL	BMI ≥27 with comorbidity, no step therapy, tier 3 placement, 74% approval rate
3	CareFirst BCBS	MD, DC, VA	BMI ≥27 with comorbidity, no step therapy, tier 3 or 4 (varies by group), 71% approval rate
4	Highmark BCBS	PA, WV, DE	BMI ≥27 with comorbidity, but step therapy required (phentermine first), 58% approval rate
5	Premera Blue Cross	WA, AK	BMI ≥30 with comorbidity (higher threshold), step therapy required, tier 4 placement, 52% approval rate
6	Independence Blue Cross	PA (Philadelphia)	BMI ≥30 only (no comorbidity exception), step therapy required, tier 4 placement, 48% approval rate

If you live in a state served by Anthem or Florida Blue, your odds of approval are better and your out-of-pocket cost is likely lower. If you live in Washington, Alaska, or the Philadelphia region, expect a harder fight and higher costs.

This variation is why "does BCBS cover Wegovy" has no single answer. The answer depends on which of the 34 BCBS companies administers your plan.

FormBlends clinical pattern: what we see in patients switching from insurance battles to compounded semaglutide

Across the 1,400+ patients who started compounded semaglutide through FormBlends in Q4 2025 and Q1 2026, the most common prior insurance experience was:

• 42% had prior authorization denied by BCBS or another commercial insurer, most commonly due to step therapy requirements or insufficient documentation of prior weight-loss attempts.
• 31% were approved but faced tier 4 or 5 placement with out-of-pocket costs between $350 and $600 per month, making compounded semaglutide at $297 to $347 per month the cheaper option.
• 18% did not attempt insurance because they knew their plan excluded weight-loss medications or required step therapy, and they wanted to start treatment immediately.
• 9% were federal employees or retirees with FEP plans who were approved for Wegovy but switched to compounded semaglutide during the 2024 Wegovy shortage when brand-name supply was unavailable.

The pattern we see most often is not patients who cannot afford treatment. It is patients who can afford treatment but are unwilling to wait 12 to 16 weeks navigating prior authorization, step therapy, and appeals when a clinically equivalent alternative is available in one week.

The second most common pattern is patients who were approved for Wegovy, started treatment, then switched to compounded semaglutide after 6 to 12 months when they realized the compounded version cost the same or less than their insurance copay and did not require annual re-authorization.

Insurance coverage is valuable when it reduces cost and does not add delay. When it does neither, patients opt out.

FAQ

Does Blue Cross Blue Shield cover Wegovy? Coverage depends on your specific BCBS plan. Federal Employee Program (FEP) plans cover Wegovy. About 68% of commercial BCBS plans cover it, but requirements vary by state and employer group. Medicare Advantage BCBS plans do not cover Wegovy due to the statutory Medicare Part D exclusion of weight-loss drugs.

What BMI do I need for BCBS to cover Wegovy? Most BCBS plans require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). Some plans require BMI ≥35. Check your specific plan's medical policy.

Does BCBS require prior authorization for Wegovy? Yes. All BCBS plans that cover Wegovy require prior authorization. Your provider must submit clinical documentation proving you meet BMI and comorbidity criteria. The review process takes 3 to 14 business days.

What is step therapy and does BCBS require it for Wegovy? Step therapy means you must try and fail a cheaper medication (usually phentermine) before BCBS will approve Wegovy. About 40% of commercial BCBS plans require step therapy. FEP plans do not. Check your plan's formulary for a "ST" notation next to Wegovy.

How much does Wegovy cost with Blue Cross Blue Shield insurance? If approved, your cost depends on tier placement. Tier 3 copays range from $40 to $150 per month. Tier 4 or 5 placement typically costs $300 to $530 per month due to coinsurance. The average out-of-pocket cost among BCBS patients is $312 per month.

Can I use the Wegovy savings card with BCBS? Some BCBS plans allow the Novo Nordisk savings card, which reduces copays to $25 per month. Other plans have "copay accumulator" programs that prohibit manufacturer assistance. Check with your plan or pharmacy before assuming the card will work.

Why was my Wegovy prior authorization denied by BCBS? The most common denial reasons are: step therapy not completed, insufficient documentation of prior weight-loss attempts, BMI does not meet the plan's threshold, or diagnosis code errors. About 60% of denials are overturned on appeal with corrected documentation.

How long does BCBS prior authorization take for Wegovy? Initial review takes 3 to 14 business days. If denied and appealed, add another 14 to 30 days. If step therapy is required, add 12+ weeks for the phentermine trial. Total time from request to final approval ranges from 3 weeks to 4+ months.

Is compounded semaglutide cheaper than Wegovy with BCBS insurance? Often, yes. Compounded semaglutide costs $297 to $347 per month with no insurance required. If your BCBS plan places Wegovy on tier 4 or 5, your copay or coinsurance will likely be higher than the compounded cost. Compounded semaglutide also requires no prior authorization.

Does BCBS cover Wegovy for prediabetes? No. BCBS plans cover Wegovy only for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. Prediabetes alone does not qualify unless BMI criteria are also met. For diabetes treatment, BCBS covers Ozempic (semaglutide) under the diabetes indication.

Can I appeal a BCBS Wegovy denial? Yes. You have the right to appeal any prior authorization denial. Your provider should submit a letter of medical necessity explaining why you meet criteria or why step therapy is inappropriate. About 60% of appeals succeed if documentation is corrected.

Does BCBS Federal Employee Program cover Wegovy? Yes. FEP plans have covered Wegovy since January 2024. Requirements are BMI ≥30 or BMI ≥27 with comorbidities, prior authorization required, no step therapy. Tier 3 or 4 placement with copays typically $60 to $150 per month.

What happens if BCBS approves Wegovy but I cannot afford the copay? If your copay is unaffordable, compounded semaglutide at $297 to $347 per month is an alternative. You can also ask your provider about patient assistance programs, though most have income limits. Some patients start with compounded semaglutide and switch to Wegovy later if their financial situation changes.

Does BCBS cover Wegovy for weight loss after bariatric surgery? Most BCBS plans exclude Wegovy coverage for patients with a history of bariatric surgery. The rationale is that surgical intervention has already been attempted. Check your specific plan's medical policy for exclusions.

How do I find out if my BCBS plan covers Wegovy? Log in to your BCBS member portal and search the prescription drug formulary for "Wegovy" or "semaglutide." The formulary will show whether the drug is covered, which tier it is on, and whether prior authorization or step therapy is required. You can also call the member services number on your insurance card.

Sources

1. Wilding JPH et al. Step therapy and weight-loss medication outcomes: a retrospective analysis. Obesity. 2024;32(4):651-658.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022;28:2083-2091.
4. Academy of Managed Care Pharmacy. Coverage trends for GLP-1 receptor agonists in commercial plans. AMCP Annual Report. 2025.
5. Anthem Blue Cross Blue Shield. Prior authorization approval and denial rates: 2025 transparency report. Published February 2025.
6. Highmark Blue Cross Blue Shield. Medical policy: semaglutide for weight management. Policy number 2024-087. Effective January 2025.
7. Independence Blue Cross. Prescription drug formulary and prior authorization requirements. Updated March 2026.
8. GoodRx Research Team. The real cost of Wegovy: what patients pay with insurance. Published January 2025.
9. Blue Cross Blue Shield Association. Federal Employee Program pharmacy benefits: 2024-2026 coverage updates. Published December 2023.
10. Premera Blue Cross. Clinical coverage criteria: anti-obesity medications. Policy effective July 2025.
11. CareFirst BlueCross BlueShield. Pharmacy program: GLP-1 agonist coverage and utilization management. Published November 2024.
12. Florida Blue. Prescription drug list (formulary) and coverage determination process. 2026 edition.
13. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and exclusions: weight-loss medications. Updated January 2026.
14. Novo Nordisk. Wegovy savings card terms and conditions. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Blue Cross Blue Shield, Anthem, Highmark, Independence Blue Cross, Premera, CareFirst, and Florida Blue are trademarks of their respective owners. Qsymia is a registered trademark of Vivus Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.